ONCODESIGN Announces the Separation of Its Two Business Lines - Service and Biotech - and Its Entry Into Exclusive Negotiations With Elyan Partners for the Sale of a Majority Stake in ONCODESIGN (Service), Followed by a Simplified Takeover Offer

The planned transactions are as follows: The subsidiarisation by ONCODESIGN of its Biotech/AI activities through a partial transfer of assets to the ONCODESIGN Precision Medicine (OPM) subsidiary

Related Keywords

Saclay ,France General ,France ,United States ,Canada ,Paris ,French ,America ,Arthur Rouill ,Fabrice Viviani ,Mathilde Bohin ,Olivier Arthaud ,Philippe Genne ,University Hospital ,Garnier Co ,Bus Service ,Edmond De Rothschild Group ,Euronext ,Drug Discovery Service ,Drug Discovery ,Artificial Intelligence ,Edmond De Rothschild Equity Strategies ,Elyan Partners ,Biotech Business Unit ,Cabinet Arthaud Associ ,Chief Executive Officer ,Supervisory Board ,French Commercial ,Controlling Stake ,Control Block ,Vincent Man ,Maxence De Vienne ,Lamy Lexel ,Edmond De Rothschild Private Equity ,North America ,Des March ,Private Equity ,Euronext Growth Market ,Business Units ,Relations Arthur Rouill ,Oncodesign ,Nnounces ,Separation ,Business ,Fines ,Service ,Biotech ,Entry ,Into ,Exclusive ,Negotiations ,Ith ,Kalyan ,Partners ,Sale ,Majority ,Stake ,Ollowed ,Simplified ,Makeover ,Offer ,